Strata Skin Sciences ( (SSKN) ) has released its Q4 earnings. Here is a breakdown of the information Strata Skin Sciences presented to its investors.
STRATA Skin Sciences, Inc. is a medical technology company focused on developing, commercializing, and marketing innovative dermatologic treatment products, including the XTRAC excimer laser, VTRAC lamp systems, and TheraClearX Acne Therapy System, primarily operating in the dermatology sector.
In its latest earnings report, STRATA Skin Sciences announced a 10% increase in fourth-quarter revenue for 2024, reaching $9.6 million compared to $8.7 million in the same period the previous year. The company also highlighted significant international growth and strategic initiatives aimed at enhancing operational efficiency and revenue generation.
Key financial metrics revealed a gross margin improvement to 60.1% in the fourth quarter of 2024, up from 55.3% in 2023. Equipment revenue saw a notable 23% increase, reaching $3.8 million, while the company successfully reduced operating expenses by 8.5% year-over-year. Strategic moves included renewing distribution agreements in China and Japan and raising $2.1 million through a direct stock offering.
Despite these positive developments, STRATA reported a net loss of $10.1 million for the full year 2024, attributed to one-time expenses and impairment charges. However, the company demonstrated resilience by implementing cost-saving measures and focusing on international market expansion, which contributed to a 41% increase in international sales during the fourth quarter.
Looking ahead, STRATA’s management remains optimistic about continued growth, particularly in international markets, and is committed to further enhancing its strategic revenue model and operational efficiencies to drive future success.